Detalhe da pesquisa
1.
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Lancet Oncol
; 20(4): 518-530, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30857956